ES2078455T3 - 3-aril-4(3h)quinazolinonas antagonistas de cck y formulados farmaceuticos de las mismas. - Google Patents

3-aril-4(3h)quinazolinonas antagonistas de cck y formulados farmaceuticos de las mismas.

Info

Publication number
ES2078455T3
ES2078455T3 ES91308324T ES91308324T ES2078455T3 ES 2078455 T3 ES2078455 T3 ES 2078455T3 ES 91308324 T ES91308324 T ES 91308324T ES 91308324 T ES91308324 T ES 91308324T ES 2078455 T3 ES2078455 T3 ES 2078455T3
Authority
ES
Spain
Prior art keywords
quinazolinones
cck
pharmaceutical
antagonists
aril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91308324T
Other languages
English (en)
Inventor
Jefferson Ray Mccowan
Kenneth Jeff Thrasher
Melvin Joseph Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2078455T3 publication Critical patent/ES2078455T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE HA ENCONTRADO QUE NUEVAS QUINAZOLINONAS SUSTITUIDAS EXHIBEN UNA UNION ESPECIFICA A RECEPTORES DE COLECISTOGUININA (CCK) EN EL CEREBRO Y/O LUGAR PERIFERICO TAL COMO EL PANCREAS Y EL ILEO. LAS QUINAZOLINONAS SON ANTAGONISTAS RECEPTORES DE CCK Y ENCUENTRAN APLICACIONES TERAPEUTICAS EN EL TRATAMIENTO DE DISFUNCIONES GASTROINTESTINALES Y DEL SISTEMA NERVIOSO CENTRAL, Y SON UTILES PARA LA REGULACION DEL APETITO EN MAMIFEROS. SE DESCRIBEN TAMBIEN FORMULAS FARMACEUTICAS PARA TALES INDICACIONES.
ES91308324T 1990-09-13 1991-09-12 3-aril-4(3h)quinazolinonas antagonistas de cck y formulados farmaceuticos de las mismas. Expired - Lifetime ES2078455T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/581,943 US5075313A (en) 1990-09-13 1990-09-13 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof

Publications (1)

Publication Number Publication Date
ES2078455T3 true ES2078455T3 (es) 1995-12-16

Family

ID=24327210

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91308324T Expired - Lifetime ES2078455T3 (es) 1990-09-13 1991-09-12 3-aril-4(3h)quinazolinonas antagonistas de cck y formulados farmaceuticos de las mismas.

Country Status (20)

Country Link
US (1) US5075313A (es)
EP (1) EP0475755B1 (es)
JP (1) JPH04247080A (es)
KR (1) KR920006350A (es)
CN (1) CN1059722A (es)
AU (1) AU641043B2 (es)
CA (1) CA2050994A1 (es)
CZ (1) CZ279774B6 (es)
DE (1) DE69113379T2 (es)
ES (1) ES2078455T3 (es)
FI (1) FI914262A (es)
HU (1) HUT59128A (es)
IE (1) IE913217A1 (es)
IL (1) IL99402A0 (es)
MX (1) MX9101035A (es)
NO (1) NO913579L (es)
NZ (1) NZ239712A (es)
PT (1) PT98915A (es)
YU (1) YU151691A (es)
ZA (1) ZA917149B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340801A (en) * 1991-05-08 1994-08-23 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having cholecystokinin and gastrin antagonistic properties
US5204354A (en) * 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP5137228B2 (ja) 2003-03-07 2013-02-06 メルク・シャープ・アンド・ドーム・コーポレーション 高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用
EP1601669B1 (en) 2003-03-07 2008-12-24 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7348338B2 (en) * 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
BRPI0412684A (pt) * 2003-07-17 2006-10-03 Plexxinko Inc compostos ppar-ativos
GB0319126D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
AU2005311826A1 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR active compounds
EP1819673A2 (en) * 2004-11-30 2007-08-22 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
CA2621275A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
RU2008108221A (ru) * 2005-09-07 2009-10-20 Плекссикон, Инк. (Us) Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
WO2007056124A2 (en) * 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
IL295088A (en) 2020-01-29 2022-09-01 Kamari Pharma Ltd Compounds and preparations for use in the treatment of skin disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ192392A (en) * 1978-12-19 1983-02-15 M Ishikawa 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones
EP0442878A4 (en) * 1988-04-05 1991-10-23 Abbott Laboratories Derivatives of tryptophan as cck antagonists

Also Published As

Publication number Publication date
MX9101035A (es) 1992-05-04
EP0475755A1 (en) 1992-03-18
JPH04247080A (ja) 1992-09-03
DE69113379D1 (de) 1995-11-02
IE913217A1 (en) 1992-02-25
IL99402A0 (en) 1992-08-18
KR920006350A (ko) 1992-04-27
YU151691A (sh) 1994-01-20
FI914262A (fi) 1992-03-14
CS279991A3 (en) 1992-04-15
US5075313A (en) 1991-12-24
FI914262A0 (fi) 1991-09-10
CA2050994A1 (en) 1992-03-14
DE69113379T2 (de) 1996-03-21
NO913579D0 (no) 1991-09-11
CZ279774B6 (cs) 1995-06-14
ZA917149B (en) 1992-05-27
AU8382991A (en) 1992-03-19
EP0475755B1 (en) 1995-09-27
HUT59128A (en) 1992-04-28
NZ239712A (en) 1993-06-25
CN1059722A (zh) 1992-03-25
NO913579L (no) 1992-03-16
PT98915A (pt) 1992-08-31
HU912921D0 (en) 1992-01-28
AU641043B2 (en) 1993-09-09

Similar Documents

Publication Publication Date Title
ES2078455T3 (es) 3-aril-4(3h)quinazolinonas antagonistas de cck y formulados farmaceuticos de las mismas.
AR002289A1 (es) Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias.
ECSP941156A (es) 3 bencilaminometil piperidinas substituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
MX9305294A (es) Compuestos de decahidroisoquinolina, procedimiento para su preparacion y formulacion farmaceutica que los comprende.
YU128091A (sh) Derivati hinuklidina
ES2151652T3 (es) Derivados de indol como antagonistas del receptor 5ht.
ES2067322T3 (es) Lactamas substituidas en n utiles como antagonistas de colecistoquinina.
ES2154674T3 (es) Derivados de 1,5-benzodiacepinas con actividad antagonista o agonista de cck.
UY28150A1 (es) Agentes terapeuticos
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
GT199800046A (es) Compuestos de pirazina.
ES2097341T3 (es) Indoles sustituidos como farmacos para el tratamiento del sida.
ES2158452T3 (es) Uso de agonistas y antagonistas de estrogenos en la fabricacion de un medicamento para el tratamiento de la ateroesclerosis, independientemente de la disminucion de lipidos.
CO4700426A1 (es) Ligandos especificos del neuropeptido y1
ES2152682T3 (es) Derivados de indolina utiles como antagonistas del receptor 5ht-2c.
ES2135412T3 (es) Uso de antagonistas o agonistas parciales del receptor 5-ht 1a para el tratamiento y la prevencion de trastornos cognitivos.
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
DE69412103D1 (de) Polyamidsäure-derivate mit antigastrin wirkung, ihre herstellung und ihre verwendung als arzneimittel
ATE113949T1 (de) Alpha-adrenergische rezeptorantagonisten.
AR029148A1 (es) Compuestos derivados de ureido piperidina, procedimiento para su obtencion, compuestos intermediarios, composiciones farmaceuticas que los contienen, y el uso de los mismos para la preparacion de medicamentos
RU92004363A (ru) 3-арил-3(3н)хиназолиноновые антагонисты холецистокинина и фармацевтическая композиция на их основе
ATE114310T1 (de) Alpha-adrenergische rezeptorantagonisten.
MX9302225A (es) Cicloalquenos y cicloalcanos 1,3-substituidos como agentes del sistema nervioso central.
ATE109483T1 (de) Alpha-adrenergische rezeptorantagonisten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 475755

Country of ref document: ES